Macquarie Group
CLDX icon

Macquarie Group’s Celldex Therapeutics CLDX Stock Holding History

Macquarie Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-942
Closed -$28.9K – 2122
2022
Q2 		$25K Hold
942
– – ﹤0.01% 2239
2022
Q1 		$32K Hold
942
– – ﹤0.01% 2277
2021
Q4 		$36K Hold
942
– – ﹤0.01% 2257
2021
Q3 		$51K Buy
+942
New +$44.2K ﹤0.01% 2229
2021
Q1 		– Sell
-4,874
Closed -$85K – 2466
2020
Q4 		$85K Buy
+4,874
New +$87.7K ﹤0.01% 1906
2019
Q1 		– Sell
-3,467
Closed -$10K – 1704
2018
Q4 		$10K Hold
3,467
– – ﹤0.01% 1923
2018
Q3 		$23K Buy
3,467
+1,060
+44% +$7.42K ﹤0.01% 1875
2018
Q2 		$18K Buy
+2,407
New +$32.2K ﹤0.01% 2071
2018
Q1 		– Sell
-193
Closed -$8K – 2197
2017
Q4 		$8K Buy
+193
New +$8.27K ﹤0.01% 2302
2016
Q1 		– Sell
-8,048
Closed -$1.89M – 1536
2015
Q4 		$1.89M Buy
8,048
+2,446
+44% +$533K ﹤0.01% 948
2015
Q3 		$886K Buy
5,602
+1,889
+51% +$535K ﹤0.01% 1153
2015
Q2 		$1.41M Buy
3,713
+733
+25% +$291K ﹤0.01% 1110
2015
Q1 		$1.25M Sell
2,980
-600
-17% -$215K ﹤0.01% 1105
2014
Q4 		$980K Hold
3,580
– – ﹤0.01% 1169
2014
Q3 		$696K Hold
3,580
– – ﹤0.01% 1213
2014
Q2 		$876K Buy
3,580
+1,667
+87% +$376K ﹤0.01% 1218
2014
Q1 		$507K Buy
1,913
+800
+72% +$306K ﹤0.01% 1280
2013
Q4 		$404K Buy
+1,113
New +$429K ﹤0.01% 1295

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Macquarie Group's CLDX Position: Q3 2022 in Review

Macquarie Group sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 942 shares — an estimated $28.9K sold.

Macquarie Group first reported a position in CLDX in Q4 2013 and held it in 18 quarters. The position peaked at $1.89M in Q4 2015. 158 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • Macquarie Group reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 942 Celldex Therapeutics shares in Q3 2022, an estimated $28.9K.
  • Macquarie Group first reported a position in Celldex Therapeutics in Q4 2013 and held it in 18 quarters.
  • Macquarie Group's Celldex Therapeutics position peaked at $1.89M in Q4 2015.
  • 158 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.